Anti-Rheumatics Market Growth Driven by Rising Prevalence of Rheumatoid Arthritis

The global anti-rheumatics market is experiencing steady growth, fueled by the surge in rheumatoid arthritis cases and the growing elderly population. According to Straits Research, the market was valued at USD 66.24 Billion in 2024 and is expected to reach USD 84.18 Billion by 2033 at a CAGR of 2.7% (2025–2033).

Download Sample

The anti-rheumatics market includes drugs used to treat rheumatoid arthritis and other connective tissue disorders such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and Sjogren syndrome (SS). These drugs are available in oral, subcutaneous, and intravenous forms, helping reduce inflammation, pain, swelling, and progression of arthritis. The increasing acceptance of these medications by rheumatologists, dermatologists, and gastroenterologists is strengthening their demand worldwide.

Market Growth Factors

Surge in Geriatric Population

The rising global elderly population is a key driver of the market. According to Straits Research, individuals typically begin experiencing rheumatoid arthritis symptoms in their 60s, and the growing senior population is significantly boosting demand for anti-rheumatics.

Rising Prevalence of Rheumatoid Arthritis

Rheumatoid arthritis affects millions globally. In the U.K., around 400,000 people live with rheumatoid arthritis, while 458,000 Australians (1.9% of the population) are diagnosed with the condition. The growing patient base is a major factor driving the demand for anti-rheumatic drugs.

Market Restraints

Patent expirations of blockbuster drugs such as Humira (adalimumab) have allowed low-cost generics to enter the market. This price competition negatively impacts revenues for major players, limiting overall market growth.

Market Opportunities

Developing economies such as India and China present significant opportunities due to their large patient populations, rising healthcare spending, and expanding pharmaceutical industry. Increased awareness and government investments in healthcare infrastructure are expected to further support market expansion in these regions.

Regional Insights

North America holds the largest market share and is projected to grow at a 3.0% CAGR. Rising rheumatoid arthritis prevalence and a large geriatric population, along with access to advanced healthcare, drive regional demand.
Europe ranks second, with a projected 2.4% CAGR, supported by an aging population, established pharmaceutical players, and higher healthcare spending.
Asia-Pacific is expected to grow the fastest due to its large population base, increasing disease prevalence, and improved access to healthcare in China and India.
LAMEA is still an emerging market, hindered by limited healthcare access and lower spending, though improving infrastructure and government investments are creating future opportunities.

Drug Class Insights

Disease-modifying anti-rheumatic drugs (DMARDs) dominate the market and are projected to grow at a 2.9% CAGR. Both conventional drugs like methotrexate and hydroxychloroquine and biologics such as Enbrel and Humira contribute to this dominance by slowing disease progression and preventing joint damage.

Type Insights

Prescription-based drugs account for the largest share and are expected to grow at a 2.8% CAGR. These include widely used therapies such as DMARDs and biologics that require professional medical guidance to ensure safe and effective treatment.

Key Players in the Anti-Rheumatics Market

According to Straits Research, the leading companies shaping the market include:

UCB S.A.
Pfizer Inc.
AbbVie Inc.
Eli Lilly and Company
Johnson & Johnson
Novartis AG
Amgen Inc.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
Merck & Co. Inc.

Recent Developments

January 2023 – DSI and IPASA partnered with SAMRC in South Spain to enhance pharmaceutical R&D and commercialization of new health solutions, with key involvement from players like Merck, Novartis, Pfizer, and Roche.
June 2022 – Cipla and DNDi launched a child-friendly 4-in-1 antiretroviral treatment in South Africa, approved by SAHPRA, improving access for young patients living with HIV.

About Us

Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.